Across TCGA pan-cancer cohorts, STIMATE Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STIMATE data layer compared with 20 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher STIMATE Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STIMATE expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, BLCA, and PRAD are the cancer types where STIMATE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
BLCA	OS	Median	All	0.187	0.720	.002	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.831	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: STIMATE tumor-vs-normal RNA expression · all STIMATE data types